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Abstract
In past, numerous methods have been developed for predicting efficacy of short interfering RNA (siRNA). However these
methods have been developed for predicting efficacy of fully complementary siRNA against a gene. Best of author’s
knowledge no method has been developed for predicting efficacy of mismatch siRNA against a gene. In this study, a
systematic attempt has been made to identify highly effective complementary as well as mismatch siRNAs for silencing a
gene. Support vector machine (SVM) based models have been developed for predicting efficacy of siRNAs using
composition, binary and hybrid pattern siRNAs. We achieved maximum correlation 0.67 between predicted and actual
efficacy of siRNAs using hybrid model. All models were trained and tested on a dataset of 2182 siRNAs and performance was
evaluated using five-fold cross validation techniques. The performance of our method desiRm is comparable to other well-
known methods. In this study, first time attempt has been made to design mutant siRNAs (mismatch siRNAs). In this
approach we mutated a given siRNA on all possible sites/positions with all possible nucleotides. Efficacy of each mutated
siRNA is predicted using our method desiRm. It is well known from literature that mismatches between siRNA and target
affects the silencing efficacy. Thus we have incorporated the rules derived from base mismatches experimental data to find
out over all efficacy of mutated or mismatch siRNAs. Finally we developed a webserver, desiRm (http://www.imtech.res.in/
raghava/desirm/) for designing highly effective siRNA for silencing a gene. This tool will be helpful to design siRNA to
degrade disease isoform of heterozygous single nucleotide polymorphism gene without depleting the wild type protein.
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Introduction
RNA interference (RNAi) is a natural mechanism evolved
in complex organisms to regulate the gene expression. This
mechanism also provide defense against viruses and transposable
material to maintain the genome integrity [1]. There has been
increasing interest to harness this mechanism to silence a specific
mRNA. RNAi is triggered whenever a cell encounter long dsRNA
molecules and subsequently cleave them into small interfering
RNAs (siRNAs) using Dicer enzyme. siRNA is ,21 nucleotide (nt)
long dsRNA having 2 nt overhang on 39-end. Afterward, siRNA
unwound and one strand associated with nuclease-containing
protein complex (RISC). Subsequently RISC containing siRNA
bind to the complementary mRNA and promotes cleavage/
degradation of mRNA [2].
siRNAs have become an important tool for silencing gene of
interest and have emerging as potential therapeutics. The beauty
of the system that makes it a powerful tool lies in sequence
specificity towards particular gene, its quick effect, and cost
effectiveness. Importantly, it makes feasible for large-scale func-
tional genomics studies. It has been shown that knockdown effect
(efficacy) of siRNA is varying according to target site on mRNA
and hence, very limited set of siRNAs show high efficacy [3].
Huesken et al. analyzed experimental data to understand
relationship between the siRNA sequence and its silencing effect
on 34 mRNA species [4]. They also developed an Artificial Neural
Network (ANN) based method BIOPREDsi and achieved
maximum correlation 0.66 between actual and predicted efficacy
[4]. In past, number of methods have been developed for
predicting efficacy of siRNA [5,6,7,8,9]. In a recent study, perfor-
mance of various methods have been evaluated which showed
BIOPREDsi, ThermoComposition21 and DSIR are highly accu-
rate and reliable methods [8,10].
Initially it was believed that full complementary siRNA is
needed to silence a target gene. However, studies have shown that
siRNA behaves like miRNA and suppress protein synthesis when it
is not fully complementary to the target, indicating mismatches are
allowed during target selection by siRNA [2,11]. This phenom-
enon also raised very important problem about off-target effect
where unintended target genes suppressed by siRNA [12,13,14]. A
study indicates that seed region of siRNA, 2-8 nt from 59-end, is
important for target finding and single mismatch within seed
region can change the off-target transcripts without effecting
silencing efficiency of original target transcript [14]. Initially off-
target sequences were searched using similarity based methods
against mRNA sequence database but the strategy was not suc-
cessful due to lack of knowledge about level of sequence similarity
required for off-target effect. To understand the silencing effect of
mismatch between siRNA and target, several studies were
conducted [15,16,17,18,19,20,21]. The study by Du et al. reveals
position of the mismatch generated in the target influence silencing
and categorized them as; (a) High tolerance: mismatch at position
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1, 2, 18, or 19, which does not affect the efficacy. (b) Low
tolerance: mismatch at position 5-11 which results into abolishing
the RNAi activity and remain position is (c) of moderate tolerance
[15]. It also showed the impact of mismatched nucleotide and
found A:C and G:U are well tolerated mismatch. Furthermore the
silencing effect of double-nucleotide mismatches were also studied
[17]. Recently, a very systematic study was conducted by using 20
siRNAs against 400 various mismatched targets to generate a
model for single nucleotide-mismatch [21]. This study analyzed all
combinations of mismatched siRNA:target and demonstrated that
efficacy can be influenced by position and type of nucleotide
mismatched. The work also demonstrated that most tolerant
mismatch was A:C while least one was A:G in term of siRNA:
target. It was observed that swapping of mismatched nucleotides at
some position dramatically changed the efficacy e.g. at position 17
of siRNA both A:C and C:A mismatched are well tolerated while
at position 12 only A:C mismatch is tolerated not C:A. However,
study also demonstrated the importance of creating mismatch
between sense and antisense strand of siRNA in order to make
more asymmetric siRNA which leads to improve silencing efficacy
[20]. In order to find off target sequence, methods has been
developed which incorporate features like seed complementary
region and nucleotide mismatch to predict potential off-targets
[22]. To the best of author’s knowledge, lack of specificity of
siRNA is considered as major drawback in designing any siRNA
based therapy.
Investigation indicates that a large portion in mRNA could not
be targeted for siRNA because of having low efficacy [3]. Thus, it
makes limited choice for selecting target site. Furthermore, the
requirement to enhance efficacy of a siRNA against particular
target site is not fulfilled by available methods. In this study, we
have examined whether weakness of siRNA (poor specificity) can
be exploited to design mutant siRNA of desired efficacy. It is well
known that all siRNAs is not equally effective even if they are fully
complementary to mRNA. On the other side, we also know from
experimental studies that few mismatches at specific position can
be tolerated. Based on this hypothesis a prediction method has
been developed for designing effective mismatch siRNA against
mRNA.
This study having two sections: (1) The development of a model
for predicting siRNA efficacy, and (2) The creation of mutation in
the siRNA sequence to enhance its efficacy. This facility is acces-
sible to scientific community through web based portal at http://
www.imtech.res.in/raghava/desirm/.
Methods
Datasets
The main dataset used in this study contains 2182 siRNAs.
All models trained, tested and evaluated using five-fold cross-
validation techniques on main dataset. This dataset was obtained
from Huesken et al. [4] and have been used for developing number
of existing methods. In order to compare performance of our
method with existing methods, we obtained benchmarking data
from Ichihara et al. [8]. This benchmarking data contains two
datasets; I) training dataset having 2431 siRNAs [consist of 2182
(main dataset) + 249 (testing dataset)] taken from [4] and ii) testing
dataset consists of 419 siRNAs [23,24,25,26,27].
Features used for models development
Composition based features. Nucleotide composition: The
nucleotide composition determines the occurrences of different
types of nucleotides, dinucleotides, trinucleotide etc. We compute
mono-, di,- tri-, and tetra-nucleotide composition of siRNAs that
generate vector of 4 (A, C, G, and U), 16 (AA, AC, AG, CG,
AU,…, UU), 64 (AAA, AAC, AAG,…, UUU), and 256 (AAAA,
AAAC, AAAG,…,UUUU) respectively.
Split nucleotide composition: In this case whole sequence was
divided into two equal parts and nucleotide composition of each
part is calculated separately. Composition of both part is used to
develop our models, in this case dimension of input vector was
doubled [28]. For instance 21 nt sequence was divided into nearly
half 11 nt and 11 nt, mononucleotide composition was calculated
for each part and combine to form vector dimensions of 8.
Higher order nucleotide composition: In simple dinucleotide
composition we considered local order (1st order) where interac-
tion between ith and (i + 1)th nucleotide is taken into account. In
case of second order dinucleotide composition, interaction of 1st
with 3rd nucleotide is considered i.e. ith and (i + 2)th. Similarly in
case of third order dinucleotide composition interaction of 1st with
4th nucleotide is considered.
Position specific features. Binary pattern of nucleotides:
This gives information about occurrences of position specific
nucleotide in siRNA sequence. In this case each nucleotide was
represented by binary pattern of dimensions four (A by [1,0,0,0],
C by [0,1,0,0], G by [0,0,1,0] and U by [0,0,0,1]). Thus, a
sequence of 21 nucleotides of miRNA was represented by a vector
of dimensions 84 (4621).
Binary pattern of dinucleotides: Instead of considering one
nucleotide as in binary pattern, occurrence of two consecutive
nucleotides at particular position was considered.
Binary of condense: Sequence was divided into two equal parts
and binary pattern of both part were calculated and merged into
each other (like hairpin structure) so that 59-end and 39-end of a
sequence are at same position.
Hydrogen bond: The hydrogen bonding properties were
depicted as ‘‘3’’ for G and C while ‘‘2’’ was assigned in case of
A and U.
Thermodynamic: The value of thermodynamic propertied at
each position were taken from [10].
Target site accessibility: Target site accessibility in terms of
probability of being unpaired is calculated using RNAplfold
[29]. We used parameter (W=80, L= 40, u = 16) for calculating
target site accessibility which was considered as the best para-
meters for differentiating between functional and non-functional
siRNA [6].
Scaling of feature: During hybrid approach various different
features were considered at a time creating a large range of feature
values that resulted into the poor performance of models [30].
Hence we normalized the values in the range of 1–10 using scaling
feature of libSVM software (http://www.csie.ntu.edu.tw/˜cjlin/
papers/guide/guide.pdf).
Prediction approaches. In order to develop models for
siRNA efficacy prediction, various features of siRNAs were used.
SVMlight [31], was implemented for models development.
Performance measures. In order to evaluate performance of
our models, we used following standard parameters; 1) correlation
coefficient (R), II) coefficient of determination (R2), III) mean
absolute error (MAE), root mean squared error (RMSE). All models
were evaluated using five-fold cross validation technique.
R~
n
Xn
n~1
Eacti E
pred
i {
Xn
n~1
Eacti
Xn
n~1
E
pred
iffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
n
Xn
n~1
Eacti
 2
{
Xn
n~1
Eacti
 !2vuut
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
n
Xn
n~1
E
pred
i
 2
{
Xn
n~1
E
pred
i
 !2vuut
Designing of Complementary and Mismatch siRNAs
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23443
R2~1{
Xn
i~1
Eacti {E
pred
i
 2
Xn
i~1
Eacti {E
act
i
 2
MAE~
1
n
Xn
i~1
Eacti {E
pred
i
 
RMSE~
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1
n
Xn
i~1
Eacti {E
pred
i
 2s
Where n is the size of test set, Ei
pred, and Ei
act is the predicted
and actual efficacy respectively. E
act
i is the average of actual
efficacy in test set.
Results
All models were trained and tested on main datasets consist of
2182 siRNAs where each siRNA is 21 nucleotides long. In this
strategy dataset was randomly divided into five sets, four sets were
used for training and remaining set for testing. This process is
repeated five times so that each set is used once for testing.
Composition based models
First, SVM based models have been developed using different
types of nucleotide compositions and obtained maximum cor-
relation of 0.574 between predicted and actual efficacy using
tetranucleotide composition. The performance of all composition-
based models has been shown in Table 1. Similarly, SVM based
models have been developed using split nucleotide composition
and achieve maximum correlation of 0.508 using trinucleotide
composition. Finally models were developed using higher order
nucleotide composition and achieved best correlation 0.579
between predicted and actual efficacy. In comparison to simple
trinucleotide composition (R= 0.574), substantial increase in
efficacy was observed using 2nd order trinucleotide composition
reveals the importance of pattern of nucleotides and influence of
single gap on efficacy (Table 1).
Models based on position specific features
One of major disadvantage of above composition based models is
that they used only frequency of different types of nucleotides and
hence do not consider the information about position of nucleotides
in siRNA. In order to overcome this problem we created binary
patterns for siRNA, which provide complete information (position
and type of nucleotide). First SVM based model was developed
using binary pattern of nucleotide composition and achieve
correlation coefficient of 0.637 (Table 2). This model outperforms
all the models based on composition, which indicate importance of
position of nucleotides in siRNA. As shown in Table 2, SVMmodels
were developed using various types of binary patterns like
dinucleotide, hydrogen bond. However, we got maximum perfor-
mance using binary pattern of nucleotides.
Hybrid models
In this study we developed models using two or more than two
types of features and called Hybrid models. First hybrid models
were developed using composition based features where two or
more than two types of compositions were used for developing
models (Table S1). Similarly, we developed hybrid models using
position specific features; we found binary pattern and thermody-
namics achieved better performance (Table S1). We also
developed hybrid models using percent nucleotide composition,
nucleotide frequency and binary pattern as input feature. Finally,
we achieved highest correlation coefficient of 0.670 by using our
hybrid model, which uses nucleotide frequency and position
specific based features (Mono+Di+Tri+Binary pattern). We called
this model desiRm21 in this study (Table 2).
Comparison with existing methods
It is important to compare performance of newly developed
method with existing methods. In order to compare any two
Table 1. Performance of SVM-based models for siRNA efficacy prediction developed using composition based features.
Composition Features Vector R R2 MAE RMSE g c j
Nucleotide Composition Mono 4 0.316 0.095 0.152 0.190 0.001 1 1
Di 16 0.450 0.145 0.145 0.185 0.001 3 2
Tri 64 0.515 0.248 0.138 0.173 0.001 1 2
Tetra 256 0.574 0.312 0.131 0.166 0.0001 10 2
Split nucleotide composition Mono 8 0.355 -0.03 0.161 0.203 0.001 1 3
Di 32 0.453 0.203 0.143 0.178 0.001 1 3
Tri 128 0.508 0.243 0.137 0.174 0.0001 2 2
Higher order composition 2nd order Di 16 0.420 0.115 0.149 0.188 0.001 1 2
3rd order Di 16 0.467 0.207 0.143 0.178 0.001 1 1
4th order Di 16 0.461 0.150 0.146 0.184 0.001 1 2
2nd order Tri 64 0.579 0.332 0.128 0.163 0.001 1 1
3rd order Tri 64 0.483 0.218 0.141 0.177 0.001 1 1
2nd order Tetra 256 0.502 0.222 0.139 0.176 0.0001 10 2
Mono: mononucleotide; di: dinucleotide; tri: trinucleotide; tetra: tetranucleotide; R: correlation coefficiet; R2: Coefficient of determination; MAE: Mean absolute error;
RMSE: Root mean square of error; g, c, and j are SVM parameters.
doi:10.1371/journal.pone.0023443.t001
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methods, one should use same dataset for training and testing.
Recently, Ichihara et al. [8] compare performance of major existing
methods. In this study we used same data for evaluating per-
formance of our newly developed method desiRm21. We trained
our model on 2431 siRNAs and tested on 419 siRNAs. As shown in
Table 3, performance of desiRm21 is comparable to previously
developed methods.
Increase of siRNA efficacy by base substitution
The siRNA pathway is a multistep procedure and one crucial
step is the integration of the guide strand into the RISC complex.
The efficiency of integration depends on the sequence of siRNA
duplexes, but likely not on the sequence of the target sites itself
[20,30]. Here in this section we propose an ingenious approach to
design non-perfect siRNAs, which are more efficient in the earlier
steps of the process such as RISC integration resulting more potent
siRNAs.
RNAi studies in human cells showed effective siRNAs may have
length from 16 to 21 nt [32], siRNA of length of 19 nt have been
successfully used to silent mRNAs [23,24,27,33]. Previously, it has
been shown that performance of siRNA prediction method
developed using 19 nt is very similar to method developed using
21 nt [8]. In order to understand the effect of mismatch between
siRNA and target, first time a systematic experimental analysis was
conducted by Liang’s group [15,17]. They used 19 nt long siRNA
for targeting human CD46 gene (XM_036622) at nucleotides
position 604–622. In order to get more insight on single-nucleotide
mismatch, same group studied all combinations of base-mismatch
across each position on target sites [21]. They employed 20
siRNAs against ,400 target sites and generate most comprehen-
sive data on efficacy of single mutation on target site. Hence, for
implementing the result of these studies we developed a SVM
model desiRm19. This model uses same nucleotide features as with
desiRm21 but on 19 nt long sequence, which were made by
removing last two bases from 39-end of each 21 nt long sequence
[34]. desiRm19 achieved correlation coefficient of 0.646, 0.648,
and 0.553 on training dataset, independent datasets of 249- and
419-sequences respectively. The performance of desiRm19 is
marginally lower than desiRm21 because of less information
content on 19 nt long sequence.
In past, several investigations reported the importance of target
site accessibility in mRNA to design effective siRNA. Hence, we
also integrated target site accessibility feature along with nucleo-
tide frequency and binary pattern feature (desiRm19) for model
development. The best SVM model (desiRm) achieved correlation
coefficient of 0.647 and 0.654 on training dataset (2182-sequences)
and independent dataset (249-sequences) respectively. The
marginal improvement in the performance was observed due to
incorporating target site accessibility information. This supports
earlier finding about the importance of this feature in designing
functional siRNA [6,35].
In order to get more potent siRNA, we generated mutation on
every position of 19 nt antisense with all four nucleotides of an
siRNA. Efficacies of these mutated siRNAs were predicted using
our SVM model desiRm. However, the mutant siRNA when
bound with target sequence caused mismatch and hence affected
the silencing efficiency. Therefore, based on the experimental data
a scoring method has been developed, which deduced effect of
position and/or identity of mismatch from predicted efficacy to
find out overall Mismatch Efficacy (ME) of mutated siRNA.
ME= predicted efficacy- S reduced efficacy (due to mismatch)
Mismatch efficacy incorporating both position and
identity of nucleotide.
Initially we generated the single mutation that makes 57
different permutation of single siRNA. The repression changes
affected by position of mismatch and identity of mismatch between
siRNA:target is taken from experimental data [21]. We obtained
the mismatch tolerance efficacy data by personal communication
with author (Figure S4 of [21]). Therefore a mismatch efficacy is
calculated by deducing efficacy due to mismatch from predicted
efficacy.
Suppose an siRNA (CAGUGGAAAGUACAUCAGA) is made
against a target region (UCUGAUGUACUUUCCACUG) in a
mRNA NM015213. The siRNA is fully complementary with
target having actual and predicted efficacy of 0.479 [4] and 0.588
respectively (Figure 1). If C is replaced by U at 1th position
(uAGUGGAAAGUACAUCAGA) its predicted efficacy will be
0.776, when it is fully complementary with target sequence. But as
we noticed that first base of siRNA causes mismatch of U:G and
causes decrease in efficacy by 0.066 (from [21]). Thus mismatch
efficacy of uAGUGGAAAGUACAUCAGA is 0.776-0.066 =
0.710. To find out efficacy of siRNA with two mismatches
experimental data were taken from Dahlgren et al., [17]. Thus,
subsequent mutations resulting siRNA of uAGUGGAAAGUA-
CAaCAGA with mismatch efficacy of 0.929.
Mismatch efficacy incorporating only position effect
The experimental studies carried out by Dahlgren et al. only
used single siRNA against mutated targets [17]. Thus, the effects
of all possible types of siRNAs and double nucleotides mismatches
were not studied. The experimental data has 709 different com-
binations for double nucleotide mismatch out of 1539 possible.
Therefore, in case of more than two mismatches or lack of
similarity with experimental data we only incorporated average
position specific effect from single-nucleotide mismatch [21]. For
Table 2. Performance of SVM-based model for siRNA efficacy
prediction developed using position specific feature and our
method desiRm.
Features Vector R R2 MAE RMSE g c j
Binary pattern 84 0.637 0.406 0.122 0.154 0.01 1 1
Binary of di 320 0.563 0.272 0.135 0.170 0.001 6 2
Binary of Condense 40 0.449 0.200 0.142 0.179 0.001 10 1
AU, GC 42 0.362 0.130 0.149 0.186 0.001 1 1
Hydrogen bond 21 0.579 0.335 0.130 0.163 0.01 2 1
Thermodynamics 19 0.577 0.332 0.129 0.163 0.001 10 1
desiRm21 168 0.670 0.448 0.118 0.148 0.001 2 1
doi:10.1371/journal.pone.0023443.t002
Table 3. Performance of desiRm21 and other four algorithms
on test dataset containing 419 siRNA.
Methods R R2 MAE RMSE
i-Score 0.557 0.217 0.243 0.284
s-Biopredsi 0.546 0.296 0.218 0.270
Thermocomposition21 0.577 0.200 0.221 0.288
DSIR 0.555 0.158 0.222 0.295
desiRm21 0.558 0.164 0.222 0.294
doi:10.1371/journal.pone.0023443.t003
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Figure 1. Schematic diagram of efficacy of complementary and mismatch siRNAs against a target site. Fully complementary siRNA has
actual and predicted efficacy of 0.479 and 0.588 respectively. Single mutation at 1st position in the siRNA has predicted efficacy of 0.776 but overall
efficacy due to single mismatch is 0.710 (0.776-0.066). Further mutation at 15th position in siRNA has predicted mismatch efficacy of 0.929. Base
pairing is denoted by ‘‘ | ’’, mismatch with ‘‘ : ’’, and mutant base with small case.
doi:10.1371/journal.pone.0023443.g001
Table 4. Comparative study of increase/decrease efficacy of siRNAs by using our method, desiRm.
siRNA antisense
Target
access
Actual
Efficacy
desiRm
Efficacy Mutated siRNA antisense
desiRm
Efficacy
Position of
Mutation
UCCUCACCAUCCGUCCAGU 0.003895 0.465 0.577 UCCUCACCcUCCGUCCAGg 0.771 9, 19
CUAAUAUGUUAAUUGAUUU 0.054683 0.462 0.647 CUAAUAUGUUAAUUGAUUg 0.813 19
CUAAUAUcUUAAUUGAUUg 0.855 8,19
uUAAUAUGUUAAUUGAUUg 0.909 1,19
CAGAUUCCACACCAUGUGG 0.000327 0.402 0.732 uAGAUUCCACACCAUGUGG 0.864 1
aAGAUUCCACACCAUGUGG 0.923 1
uAGAUUCCACACCAaGUGG 1.033 1,15
uAGAUUCCACACCAcGUGG 0.148 1, 15
uAGAUcCCACACCAUGUGG 0.061 1,6
GGUCCACAUUCUAUUUUAA 0.007570 0.388 0.397 aGUCCACAUUCUAUUUUAA 0.628 1
uGUCCACAUUCUAUUUUAg 0.798 1, 19
uGUCCACAUUCUAUUUUcg 0.757 1, 18, 19
CCUCACCAUCCGUCCAGUA 0.002853 0.326 0.473 aCUCACCAUCCGUCCAGUA 0.653 1
uCUCACCAUCCGUCCAGUg 0.760 1, 19
UGUCUACAAUCCACUGUGU 0.008437 0.993 0.878 UGUCUACAAaCCACUGUGU 0.188 10
UGUCUACAuUCCACUGUGU 0.038 9
AACUUCUUGGCUUUGUACU 0.023926 0.995 0.895 AACUUCUUGuCUUUGUACU 0.228 10
AACAGCUCCGGAUUCUGUG 0.000321 0.978 0.926 AACAGCUCCGGAUaCUGUG 0.273 14
AACAGCUCCcGAUUCUGUG 0.260 10
AACAGCUCCGGAUUaUGUG 0.189 15
UAGAAAUGCACACAUCACC 0.001601 0.947 1.019 UAGAAAUGCACAaAUCACC 0.343 13
AAAACUUCACUACAAAUUC 0.008497 0.967 0.914 AAAACUUCuCUACAAAUUC 0.083 9
AAAACUUCAaUACAAAUUC 0.027 10
Sequence taken from Huesken data, mutated nucleotide is denotes in lower case. Target access: probability of being unpaired at target site calculated by RNAplfold.
doi:10.1371/journal.pone.0023443.t004
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position specific mismatch, average effect of that position was
considered (Figure S1).
Description of web server
A user-friendly webserver has been developed on SUN server
under Solaris environment using HTML, PERL, and CGI-PERL.
There are two input fields; (1) submit mRNA: effective siRNA
can be detected against the mRNA (Figure S2). The output result
is in descending order of efficacy that contains sequences of
antisense with fully complementary target sequence, position in
mRNA, target site accessibility and its efficacy (Figure S3). If one
wants to further increase the potency of siRNA then more
efficacious antisense sequence can be clicked which is submitted
automatically to generate single mutant siRNAs and rank them
according to ME efficacy (Figure S4). The output result shows the
position of mismatch, mutated nucleotide, target site accessibility
as well as targets sequence. The increase in efficacy using mutation
can also be obtained directly by using second input field, (2)
submit siRNA, where user can put its 19 nt long antisense
siRNA generated from other software and its target sequence.
However, this field did not consider the target site accessibility
feature during efficacy calculation. Further mutations in siRNA
can be generated by clicking the antisense sequence. This strategy
can also be used to generate siRNA with very low efficacy against
an off-target.
Comparison of efficacy due to mismatch
An analysis was carried out to assess the effect on efficacy due to
mismatch between siRNA and target sequence. We considered
mutant siRNAs sequence against a particular target. By using our
server it was found that 1–2 mutation can be use to reverse the
efficacy of a siRNA from ineffective to effective and vice-versa but
need experimental verification (Table 4). Therefore, in order to
evaluate real performance of desiRm, we evaluated its perfor-
mance on experimentally verified 78 mutated siRNA, taken from
Ohnishi et al. [36]. In this study, they design allele specific siRNA
to degrade mutant mRNA of human Prion Protein (PRNP) gene
without depleting wild type transcript (Figure S5). They utilized
same strategy which we are proposing, i.e. targeting same site with
different siRNAs (each siRNA having one-base substitution at
different position) to manipulate the efficacy of siRNA and to get
those siRNAs which can better discriminate between mutant and
wild type target. Thus siRNA give rise to single-nucleotide
mismatch with mutant-target while two-nucleotide mismatch with
wild-type. They reported that introducing base-substitution at
specific position in siRNA depleted the mutant transcript while
least affected on wild-type. When we predict the efficacy of siPrnp
102 (T9) by desiRm a correlation coefficient of 0.725 was achieved
between actual and predicted efficacy (Table 5). This high
correlation supports the applicability of our tool in real life.
Furthermore, we also used desiRm on another set of siRNA data
Table 5. Assessment of desiRm on experimentally verified mismatched siRNAs of siPrnp102(T9).
Name of siRNA
siRNA sequence (antisense)
Mutated sequence
# Mismatch
(mRNA) Target sequence
siRNA:Target (base
mismatch position
on siRNA)
Actual
Efficacy
Predicted
efficacy
siPrnp102(T9) UGGCUUACUCAGCUUGUUC 0 (mutant) GAACAAGCUGAGUAAGCCA 0 0.972 0.942
siPrnp102(T9)-5U UGGCUUACUCAGCUaGUUC 1(mutant) GAACAAGCUGAGUAAGCCA A:A(15) 0.953 0.199
siPrnp102(T9)-6U UGGCUUACUCAGCaUGUUC 1(mutant) GAACAAGCUGAGUAAGCCA A:A(14) 0.864 0.267
siPrnp102(T9)-7C UGGCUUACUCAGgUUGUUC 1(mutant) GAACAAGCUGAGUAAGCCA G:G(13) 0.867 0.531
siPrnp102(T9)-12C UGGCUUAgUCAGCUUGUUC 1(mutant) GAACAAGCUGAGUAAGCCA G:G(8) 0.931 0.645
siPrnp102(T9)-13A UGGCUUuCUCAGCUUGUUC 1(mutant) GAACAAGCUGAGUAAGCCA U:U(7) 0.951 0.821
siPrnp102(T9)-14U UGGCUaACUCAGCUUGUUC 1(mutant) GAACAAGCUGAGUAAGCCA A:A(6) 0.949 0.571
siPrnp102(T9)-15U UGGCaUACUCAGCUUGUUC 1(mutant) GAACAAGCUGAGUAAGCCA A:A(5) 0.964 0.720
siPrnp102(T9)-16C UGGgUUACUCAGCUUGUUC 1(mutant) GAACAAGCUGAGUAAGCCA G:G(4) 0.850 0.664
siPrnp102(T9)-17G UGcCUUACUCAGCUUGUUC 1(mutant) GAACAAGCUGAGUAAGCCA C:C(3) 0.941 0.782
siPrnp102(T9) UGGCUUACUCaGCUUGUUC 1 (wt) GAACAAGCCGAGUAAGCCA A:G (11) 0.763 0.450
siPrnp102(T9)-5U UGGCUUACUCaGCUaGUUC 2 (wt) GAACAAGCCGAGUAAGCCA A:A(15)/A:G (11) 0.513 0.150
siPrnp102(T9)-6U UGGCUUACUCaGCaUGUUC 2 (wt) GAACAAGCCGAGUAAGCCA A:A(14)/A:G (11) 0.403 0.134
siPrnp102(T9)-7C UGGCUUACUCaGgUUGUUC 2 (wt) GAACAAGCCGAGUAAGCCA G:G(13)/A:G (11) 0.400 0.033
siPrnp102(T9)-12C UGGCUUAgUCaGCUUGUUC 2 (wt) GAACAAGCCGAGUAAGCCA G:G(8)/A:G (11) -0.041 0.143
siPrnp102(T9)-13A UGGCUUuCUCaGCUUGUUC 2 (wt) GAACAAGCCGAGUAAGCCA U:U(7)/A:G (11) 0.183 0.286
siPrnp102(T9)-14U UGGCUaACUCaGCUUGUUC 2 (wt) GAACAAGCCGAGUAAGCCA A:A(6)/A:G (11) -0.135 0.176
siPrnp102(T9)-15U UGGCaUACUCaGCUUGUUC 2 (wt) GAACAAGCCGAGUAAGCCA A:A(5)/A:G (11) 0.388 0.217
siPrnp102(T9)-16C UGGgUUACUCaGCUUGUUC 2 (wt) GAACAAGCCGAGUAAGCCA G:G(4)/A:G (11) 0.126 0.265
siPrnp102(T9)-17G UGcCUUACUCaGCUUGUUC 2 (wt) GAACAAGCCGAGUAAGCCA C:C(3)/A:G (11) -0.063 0.178
siPrnp102(T9) and its various mutant siRNAs were targeted against prion protein genes (PRNP) and its mutant allele (PRNP-P102L). Mutated base in siRNA is denoted by
small letter while mismatch base between siRNA and target are denoted by bold letter. Data of actual efficacy of siRNAs were taken from experimental work reported by
Ohnishi et al [36]. Predicted efficacy denotes efficacy of desiRm. All sequences are in 59 to 39 direction. Correlation coefficient between actual and predicted efficacy is
R =0.725.
doi:10.1371/journal.pone.0023443.t005
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and achieved correlation coefficient of 0.586, 0.607 and 0.666
between actual and predicted efficacy for siPrnp105(T10),
siPrnp102(T10) and siPrnp178(A9) respectively (See Table S2,
S3, S4).
Discussion
It is well known that final outcome of siRNA efficacy is the
contribution of efficacy gain at each step of RNAi pathway from
loading of guide strand into RISC, target accessibility, and
cleavage efficiency [23,30,37,38]. However, their degree of con-
tribution is not fully known. Taken together these studied indicate
that there are rooms to make mutations in siRNA which become
more accessible to different proteins involved in RNAi pathway to
enhance the silencing effect. In past, various regression methods
were developed to predict the efficacy of siRNA using large
experimental data. But there is lack of method that can design the
highly effective siRNA by generating mismatch between siRNA
and target sequence. The principle of our method is to design
siRNAs, which gain efficacy at various steps of RNAi pathways
and at last step, silencing, incorporate the mismatch effect with
target site.
Here first we have developed robust SVM model for efficacy
prediction of siRNA using nucleotide features. Although we got
similar performance of our method, desiRm, as other methods but
extensive improvement of performance was not possible even
using other various nucleotide features. Several studies indicated
that target site accessibility can improve the siRNA efficacy
[6,35,39]. Thus we integrated the target site accessibility feature
along with nucleotide features and achieved marginally better
performance of model. This final model was implemented with
mismatched-tolerance data. In the mismatch efficacy prediction
we have incorporated both position as well as identity of
nucleotide for single, double-nucleotide mismatch taken from
experimental data [17,21]. Dahlgren et al. only used single siRNA
in their study, thus all possible combination of siRNA and double-
nucleotide mismatch was not covered. Therefore, in case of more
than two mismatches or lack of similarity with experimental data
we only incorporate average position specific effect from single-
nucleotide mismatch [21]. A previous method developed specific-
ity score to find out off-target genes but only considered position
specific effect from single-nucleotide mismatch data from Du el al.
[15,22]. However, Du et al. studied the effect of 57 combinations of
mismatch while 219 combinations of mismatched out of 228 was
covered by Huang et al. across all target position [15,21]. Thus we
implemented most comprehensive data of Huang et al. in desiRm.
Several studies showed the importance of mismatch siRNA for
targeting disease associated SNP genes without effecting the
normal gene [20,21,36,40,41]. Performance of our method on
experimental data showed better correlation coefficient on
mismatch efficacy (R=0.725) than that of SVM model (R=
0.647) indicating usefulness of desiRm for predicting mutant
siRNA.
Conclusions
In this study we have developed a method to design siRNA
against fully complementary as well as partial complementary
region. This novel method helps to make siRNA of desired efficacy
without changing the target site. This is very important because
some region in mRNA can be best candidate because of having
least similarity with non-intended mRNA but at same time having
lowest efficacy. Furthermore, our method helpful to design siRNA
against SNP associated disease causing gene and mutation prone
virus like HIV.
Supporting Information
Figure S1 Position specific effect on efficacy due to
single-nucleotide mismatch. Position 1,2,3, 18 and 19 were
highly tolerable i.e. efficacy is least affected.
(PDF)
Figure S2 Snapshot of desiRm input field where mRNA
can be submitted to get siRNAs.
(JPG)
Figure S3 Snapshot of desiRm output result with fully
complementary siRNAs. Each row contains sequence of
siRNA, target position, target sequence and accessibility with
predicted efficacy. To improve the efficacy of 197th siRNA targeting
on 164th position (highlighted), click this sequence.
(JPG)
Figure S4 Snapshot of desiRm output result with single-
mutated siRNAs. Each row contains mutated siRNA, position
of mutation, type of mutation, target sequence and accessibility,
with predicted efficacy. First sequence (WT) is original, mutation
at 1st position in siRNA increase their efficacy to 0.710. Further
improvement could be achieved by click on siRNA.
(JPG)
Figure S5 Complete CDS ofHomo sapiens prion protein
(PRNP) gene (wild type). The nucleotides in bold and red color
indicate the position of nucleotide variation in mutant genes reported.
Mutant PRNP-P102L has mutation at position 377(CRU); mutant
PRNP-P105L has mutation at position 386(CRU); mutant PRNP-
D178N has mutation at position 564(GRA). Highlighted regions are
targeted by siRNAs in both wild type and mutants by Ohnishi et al.
(PDF)
Table S1 Performance of SVM-based model for siRNA
efficacy prediction developed using hybrid of features.
(DOCX)
Table S2 Assessment of desiRm on experimentally
verified mismatched siRNAs of siPrnp105(T10).
siPrnp105(T10) and its various mutant siRNAs were targeted
against prion protein genes (PRNP) and its mutant allele (PRNP-
P105L). Mutated base in siRNA is denoted by small letter while
mismatch base between siRNA and target are denoted by bold
letter. Data of actual efficacy of siRNAs were taken from
experimental work reported by Ohnishi et al. Predicted efficacy
denotes efficacy of desiRm. All sequences are in 59 to 39 direction.
Correlation coefficient between actual and predicted efficacy is
R= 0.586.
(DOCX)
Table S3 Assessment of desiRm on experimentally
verified mismatched siRNAs of siPrnp102(T10).
siPrnp102(T10) and its various mutant siRNAs were targeted
against prion protein genes (PRNP) and its mutant allele (PRNP-
P102L). Mutated base in siRNA is denoted by small letter while
mismatch base between siRNA and target are denoted by bold
letter. Data of actual efficacy of siRNAs were taken from
experimental work reported by Ohnishi et al. Predicted efficacy
denotes efficacy of desiRm. All sequences are in 59 to 39 direction.
Correlation coefficient between actual and predicted efficacy is
R= 0.607.
(DOCX)
Table S4 Assessment of desiRm on experimentally
verified mismatched siRNAs of siPrnp178(A9). siPrnp178
(A9) and its various mutant siRNAs were targeted against prion
protein genes (PRNP) and its mutant allele (PRNP-D178N).
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Mutated base in siRNA is denoted by small letter while mismatch
base between siRNA and target are denoted by bold letter. Data of
actual efficacy of siRNAs were taken from experimental work
reported by Ohnishi et al. Predicted efficacy denotes efficacy of
desiRm. All sequences are in 59 to 39 direction. Correlation
coefficient between actual and predicted efficacy is R=0.666.
(DOCX)
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